THE FDA EXPANDED ITS APPROVAL OF IMFINZI®. The immunotherapy treatment is now available
as a standard-of-care option for patients with stage III non-small cell lung cancer. The expanded use
approval stems from a global clinical trial led by Moffitt thoracic oncologist Scott J. Antonia, MD, PhD.
MOFFITT MCKINLEY OUTPATIENT CENTER OPENED ITS SIXTH FLOOR ON MARCH 12.
The newly opened area houses the Senior Adult Oncology Program, GeneHome (a high-risk cancer screening
clinic), Survivorship Program, Breast Plastic Surgery, Genetic Risk Assessment, Cardio-Oncology,
Integrative Medicine-Massage Therapy and Multi-Specialty Clinic.
THE FDA APPROVED LUTATHERA® TO TREAT A RARE FORM OF CANCER. When injected into the
patient, the treatment delivers a high dose of targeted radiation to gastroenteropancreatic neuroendocrine
tumors. Moffitt oncologist Jonathan R. Strosberg, MD, led an international clinical trial leading to the
approval.
